Proteomics International partners with QIMR Berghofer Medical Research Institute (QIMR Berghofer) to improve detection of oesophageal adenocarcinoma, the most common oesophageal cancer.
The Partnership will use the Promarker™ platform with QIMR Berghofer biomarkers to develop a simple blood test for a cancer whose incidence is rising rapidly.
The collaboration is part of Proteomics International’s strategy to continually expand its diagnostics portfolio in areas of significant unmet medical need.